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Abstract 
Antibiotic resistance is by far one of the most important health threats of our time. Only a global concerted effort of 
several disciplines based on the One‑Health concept will help in slowing down this process and potentially mitigate 
the ruin of healthcare we have come to enjoy. In this review, we attempt to summarize the most basic and important 
topics that serve as good information tools to create Awareness. The Availability of antibiotics or the lack thereof is 
another significant factor that must be given thought, and finally because antibiotic resistance is a problem that will 
not go away, it is important to have Alternatives. Together, we have the 3As, essential concepts, in dealing with this 
growing and complex problem.
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Background
Antibiotics—a medical blessing
Antibiotics changed the face of medical practice. What 
was perceived as the greatest weapon in fighting infec-
tion yet, soon initiated a series of unstoppable events, 
the brunt of which we bear today: antibiotic resistance. 
Each time antibiotics are administered sensitive bacteria 
are slowly wiped out and resistant bacteria thrive. Often, 
antibiotics are still prescribed carelessly and sold with-
out a prescription, by health professionals in many parts 
of the world [1]. Moreover, they are not just restricted 
to the treatment of humans but are also widely used in 
veterinary medicine. It is currently estimated that every 
year around 700,000 deaths are associated with drug 
resistance globally [2]. More people die from drug resist-
ant infections than they do from measles and rabies 
put together (ca. 190,000 deaths globally) [3]. In Ger-
many alone, around 400,000–600,000 people develop a 
nosocomial infection annually, of which 30,000–35,000 
are caused by a multidrug-resistant organism [4] and it 
is estimated that the number of patient deaths due to 
multidrug-resistance lie between 1000 and 4000 [4]. 
A study analyzing the resistance situation in Germany 
showed that MRSA-resistance  rates and the prevalence 
of methicillin-resistant Staphylococcus aureus (MRSA) 
have remained at a  stable level over the last few years, 
however, vancomycin-resistant enterococci (VRE) and 
multidrug-resistant Gram-negative (MRGN) bacteria 
have increased considerably [5]. There also is a rising ten-
dency in the presence of carbapenem-resistant Klebsiella 
pneumoniae isolates, as published by the antibiotic resist-
ance surveillance (ARS) of the Robert Koch Institute, the 
national health institute in Germany (ars.rki.de) [6].
Antibiotic resistance threatens global public health, 
and the judicious use of antibiotics is required more than 
ever before. The key lies in the ‘One-Health’ approach 
which necessitates a collaboration between the human 
and veterinary medical sectors to better understand the 
relationship between humans, animals and their environ-
ment with respect to their health.
Awareness
Antibiotic resistance and the One‑Health concept
It was the famous Rudolf Virchow, who made the link 
between infections in humans and animals, and coined 
the term zoonosis. His fascination for helminthology 
especially the life cycle of the nematode Trichinella 
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spiralis inspired by his childhood spent watching 
butchers at work made him a prominent advocate of 
meat inspection, a factor vital to public health, though 
it was the renowned veterinarian Robert von Ostertag 
who eventually came up with the first Handbook of 
Meat Inspection several years later [7, 8]. Sir William 
Osler, father of modern medicine, backed this concept 
to a great extent, though it was Calvin Schwabe, a twen-
tieth Century veterinarian, who is said to have come 
up with the expression One-Medicine and propagated 
its practice in modern times [9]. Today we know this 
concept as One-Health which recognizes that human 
health is linked with the health of animals and the envi-
ronment, and only a concerted effort of multiple disci-
plines and the bridging of the two professions (human 
and veterinary medicine) globally can achieve optimal 
health for humans and animals (Fig.  1). Zoonotic dis-
eases are those that can be transferred between humans 
and animals. Over 60% of all known pathogens that 
infect humans are zoonotic in nature [10, 11].
Escherichia coli is a bacterium that makes up part of 
the intestinal microbiota in both humans and animals. 
Given the right setting, however, these bugs can often 
cause mild to very severe infections, posing a problem 
for both human and veterinary medicine. Antibiotics 
have, however, now lost the power to treat many E. coli 
infections, the most common of these being those caused 
by extended spectrum β-lactamase (ESBL) producing E. 
coli, which are resistant to several β-lactam antibiotics, 
including the penicillins and cephalosporins and which 
are now widespread among both humans and animals 
[11, 12].
The appearance of genetically similar drug-resistant 
strains across several species is a further cause for worry. 
In 2014 Ewers et  al. published the results of a study, 
which identified a novel genotype among certain ST648 
extraintestinal pathogenic E. coli (ExPEC) subgroups of 
Fig. 1 Infographic about the One‑Health Concept considering all aspects of life
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the phylogenetic lineage D, isolated from animals. This 
genotype combined both multiresistance (CTX-M) and 
extraintestinal virulence [13]. It was interesting to find 
the CTX-M-15 genotype, a human linked β-lactamase 
type prevalent among companion animal isolates. The 
study concluded that non B2 lineages were relevant to 
both humans and animals and that ST648 strains were 
potentially zoonotic. A year later, when analysing fae-
ces from dogs within a clinical and non-clinical setting, 
Schaufler et al. found high rates of ESBL producing E. coli 
shed by dogs outside the clinical setting. What was more 
alarming was that when comparing strains from dogs in 
a clinical and non-clinical setting, several strains were 
found to be clonal [14]. Such findings started to become 
a regular occurrence. In 2016, Schaufler et al. once again 
provided evidence for an interspecies transmission of 
a new successful ESBL producing E. coli clone (ST410) 
between wildlife, humans, companion animals and the 
environment [15]. Meanwhile McNally et al., when stud-
ying the ecology of another multidrug-resistant E. coli 
lineage ST131, which is pandemic, looked at it from a 
different perspective of lineage evolution that combines 
core, accessory and gene regulatory region genome anal-
ysis. They found that human, dog, cat and wild bird iso-
lates can move freely across niches, without any obvious 
signals of ecological adaptation and niche segregation, 
once again providing evidence for the zoonotic nature 
of this clone [16]. In a separate study Günther et  al. 
emphasized the global environmental dimension and 
zoonotic character of ESBL producing E. coli, after find-
ing similarities between Mongolian wildlife isolates and 
European clinical isolates, and observing that environ-
mental isolates harbour stably integrated, chromosomally 
encoded resistance factors [17], while yet another study 
revealed that green sea turtles might be harbouring and 
spreading superbugs near the Great Barrier Reef. Entero-
bacteriales were isolated from cloacal swabs of captured 
green sea turtles, and found to be resistant to twelve dif-
ferent antibiotics from six different classes [18]. Almost 
40% of the isolated Enterobacteriales were found to be 
multidrug-resistant.
With global travel surging, the crowded skies are not 
just a worry for aviation agencies and air traffic control-
lers, but for public health experts alike. In 2015 Lübbert 
et  al. examined stool samples from travellers returning 
to Germany and found that 30% were colonized by ESBL 
E. coli following their travel, with those travelling back 
from India showing the highest colonization levels of 
ESBL producing Enterobacteriaceae (73%) [19]. This was 
confirmed in 2016, when it was reported that travellers 
returning from India and Southeast Asia were a relevant 
source of spread of multidrug-resistant E. coli [20]. Look-
ing at it from a different perspective Bengtsson-Palme 
et  al. examined stool isolates of Swedish students on 
exchange programs in the Indian peninsula and central 
Africa. They concluded that the human microbiome acts 
as a vehicle for antibiotic resistance genes, while main-
taining a stable taxonomic diversity [21].
The worldwide prevalence of an important drug-resist-
ant pathogen methicillin-resistant Staphylococcus aureus 
(MRSA) is well documented. Hospital-acquired (HA), 
Community-acquired (CA) and Livestock-associated 
(LA) MRSA are the most common terms used to cat-
egorize the incidence of MRSA. Cuny et  al. reported in 
2015 that 10% of the MRSA isolated from humans were 
in fact LA-MRSA [22]. In addition, the study showed, 
that 77–88% of humans with exposure to pigs on farms 
were likely to show nasal colonization of MRSA, of which 
transfer to family members occurred in 4–5% of these 
cases. This suggests that pig farmers can be easily colo-
nized by MRSA which therefore places them in a risk 
category in the recommendations for the prevention and 
control of MRSA. While being colonized by MRSA is 
no cause for worry, certain predisposing conditions like 
a weakened immune system or invasive surgeries could 
make it conducive for severe infection which is then dif-
ficult to treat.
Close contact with animals whether based on occupa-
tion (farming industry) or simply by having pets at home, 
provides many opportunities for pathogens, including 
drug-resistant bacteria to be exchanged between humans 
and animals [23]. Walther et al. described this when they 
found pets and their owners colonized by Staphylococ-
cus pseudintermedius in a study in 2012 [24]. They also 
reported a novel MRSA variant identified in companion 
animals, which was not restricted to humans or rumi-
nants, therefore suggesting a potential zoonotic risk of 
this pathogen [25]. Additionally, Vincze et al. showed in 
separate studies that methicillin resistant and suscepti-
ble S. aureus strains from companion animal infections 
were highly similar to strains from human infections and 
colonization [26, 27]. These shared S. aureus populations 
serve as indicators for a potential exchange of strains 
between humans and companion animals. Previously, 
Paterson et al. were able to prove a direct MRSA trans-
mission between infected dogs and colonized humans in 
both directions [28]. When analyzing the possibility of 
contamination of commercial poultry meat (broiler and 
free-range) with pathogenic or multidrug-resistant E. coli 
in retail chain poultry meat markets in India, Hussain 
et al. found a higher prevalence of ESBL—E. coli among 
broiler chickens, and confirmed two globally emergent 
human pathogenic lineages of E. coli, suggesting that 
poultry may be an indirect public health risk, by being a 
possible carrier of non-pathogenic multidrug-resistant E. 
coli as well as human E. coli pathotypes [29]. With all the 
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evidence piling up, the need of the hour is dealing with 
this problem, which is only possible in a combined effort 
of interdisciplinary sectors modelled on the One-Health 
concept, to help slow down the spread of drug-resistance.
What came first, antibiotics or resistance?
In 2011, a group of scientists dug up ancient DNA hid-
den and preserved below ground at Dawson City, Yukon, 
which lies on the Tintina Fault, with its subarctic climate, 
population of 1375 and underlain with permafrost. They 
reported targeted metagenomics analyses of rigorously 
authenticated DNA, obtained from 30,000-year-old Ber-
ingian permafrost sediments [30] and went on to identify 
a highly diverse collection of genes encoding resistance to 
ß-lactam, tetracycline and glycopeptide antibiotics. Pre-
viously, the same group suggested that soil could serve 
as an under recognized reservoir for resistance that has 
already emerged or has the potential to emerge in clini-
cally important bacteria [31]. Their research findings 
are proof of antibiotic resistance being a natural phe-
nomenon. This is significant when human and veteri-
nary medical sectors work together using a One-Health 
approach. In a study in Germany, GPs, hospital physi-
cians, pig farmers, veterinarians and members of the gen-
eral public were surveyed to understand the perceptions 
and attitudes towards antibiotic resistance. Each group 
tended to identify drivers of antibiotic resistance as being 
from outside their own area of activity [32]. When talking 
about the problem of resistance to antibiotics, playing the 
blame game is futile, because antibiotic resistance does 
eventually find its way into the ecosystem.
To understand this, one must once again go back to the 
fundamentals of microbiology. There are several mecha-
nisms by which an organism becomes resistant to anti-
biotics (Fig.  2), but a distinction is to be made between 
natural (intrinsic) resistance and acquired resistance 
[33]. Natural resistance describes the intrinsic proper-
ties of a bacterium which do not permit an antibiotic to 
work. Acquired resistance on the other hand describes 
the resistance of a bacterium to an antibiotic to which 
it was previously susceptible. Additionally, bacteria can 
become resistant through the acquisition of extrachro-
mosomal elements or foreign DNA carrying information 
for antibiotic resistance, the best example being, colistin 
resistance, transferred by the mcr gene harboured on a 
plasmid [34]. This kind of resistance is crucial, as it can 
spread easily between and across bacterial species.
Antibiotics: knowing when, knowing how
Sometimes, choosing and prescribing antibiotics can be 
quite a predicament for professionals. As a start, the pre-
scriber needs to be certain that prescribing the antibiotic 
Fig. 2 Infographic about the mechanisms of antibiotic resistance in bacteria
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is the correct choice in that individual situation, in order 
to avoid unnecessary use of antibiotics. Following the 
initial decision, choosing the right antibiotic might be 
the next hurdle. Good antimicrobial stewardship is the 
rational and responsible use of antibiotics and focusses 
on the choice of antibiotic, therapy duration and dose, 
route of administration, as well as evidence of a bacterial 
infection [35]. The aim of antimicrobial stewardship is to 
obtain the best clinical outcome and reduce toxicity for 
the patient, while simultaneously ensuring reduced selec-
tion and resistance [35, 36]. Antimicrobial stewardship 
programmes are important in hospitals and clinics, with 
infectious disease specialists, clinical microbiologists and 
clinical pharmacists working together to constitute the 
core of such programmes promoting responsible anti-
biotic use [37], though such programmes are not imple-
mented everywhere. Medical professionals must be given 
appropriate training in good antimicrobial stewardship 
in order to encourage rational prescribing of antibiotics 
in private practices and outpatient clinics. With success-
ful antimicrobial stewardship programmes and trainings 
in place, a significant contribution can be made towards 
reducing and slowing down the development and spread 
of resistance.
Antimicrobial stewardship programmes can extend 
beyond human medicine into the veterinary sector. For 
example, when selecting an appropriate antibiotic for 
treating infections in farm animals, one must consider 
many factors, including diagnosis, route of administra-
tion, duration of therapy, spectrum of activity, herd-spe-
cific resistance problems, type of activity (Bacteriostatic 
vs. Bactericidal) and pharmacokinetics (Fig.  3), much 
like it ought to be done in human medicine. In addition, 
antibiotics must be approved for the specific treatment, 
and “Reserve antibiotics” must be thought about very 
carefully before being selected. When treating bacterial 
infections, using single antimicrobials (monotherapy) 
over combinations might be a good idea. A combination 
of bacteriostatic and bactericidal antibiotics could result 
in reduced effectivity against the pathogen being treated 
[38–40]. In the event of a secondary bacterial infection or 
mixed infections a combination therapy only makes sense 
if no antibiotic can be found that would effectively kill 
every pathogen in question. This applies to both human 
and veterinary medicine.
The World Health Organisation (WHO) very recently 
updated their ‘Essential Medicines List’ with new advice 
on the use of antibiotics. Experts have placed antibiot-
ics into three categories—Access, Watch and Reserve—
with recommendations on when these should and can 
be used [41]. The purpose of the new recommendation is 
to ensure that antibiotics are available to everyone when 
Fig. 3 Infographic depicting the possibilities of combining antibacterial agents
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they are absolutely required, infection-appropriate anti-
biotics are prescribed, development of antibiotic resist-
ance is reduced and “last-resort” antibiotics are saved for 
a time when all other antibiotics fail.
To deal with one of the most complex problems affect-
ing global health, one must therefore understand the 
problem in its entirety. Antibiotic resistance affects many 
spheres of life with many factors driving its spread. There 
is no easy way out; and so, we have first in foremost sum-
marized the most basic and important topics that serve 
as good information tools to create Awareness, which can 
assist us in dealing with the problem of antibiotic resist-
ance. In a One-Health scenario each one has their part to 
play and if done well, it stands to benefit every sector in 
question.
Awareness, however, also goes beyond basic knowl-
edge of antibiotic resistance. A significant aspect here 
is an awareness about the problems of failing antibi-
otics and the consequences of untreatable infections 
which is crucial for the rational and appropriate use of 
antibiotics. Conversely the lack of awareness can cre-
ate uncertainty and poor judgement in prescribers and 
patients alike. A recent study showed that patients who 
have used antibiotics might have more knowledge as 
a result of them having to deal with the topic of anti-
biotic use, and the authors suggest that health literacy 
could be a preventive mechanism with regard to using 
antibiotics critically [42]. Worldwide, educational pro-
grammes and campaigns are being successfully imple-
mented in an effort to create awareness not just among 
professionals, but among the general public as well 
[43–46]. In Germany, much is being done in an effort 
to deal with the problem of antibiotic resistance. Pri-
orities for antibiotic resistance prevention are set at dif-
ferent levels: nationally with the German Antimicrobial 
Resistance Strategy (DART2008, updated in 2015) and 
regionally by networks created in 2004 with support 
from the National Public Health Institute, the Robert 
Koch Institute [47]. The 2015 German national action 
plan on drug resistance, DART2020, aims at imple-
menting and strengthening the One-Health concept 
nationally and internationally, detect early resistance 
development, improve therapeutic options, prevent 
infections, create awareness, as well as support further 
research that would be beneficial in the fight against 
resistance [48]. A good example of one such research 
projects, funded by the Federal Ministry of Educa-
tion and Research (BMBF), is InfectControl 2020: a 
consortium of academics and business partners com-
ing together to find solutions on a national level. For 
the first time in Germany, a pilot project of Infect-
Control 2020, Rational Antibiotic Use via Information 
and Communication (RAI), which is modelled on the 
One-Health concept, has brought together stakehold-
ers from various areas of human and veterinary medi-
cal sciences as well as the communication sciences to 
address this issue [49]. The RAI-project (http://www.
rai-proje kt.de) aims at promoting rational antibiotic 
use in veterinary medicine, in particular, pig farming, 
as well as in human medicine, surgery and intensive 
care units, travel medicine, and primary care, primarily 
through awareness and intervention strategies [32, 50].
Availability
The availability of antibiotics or the lack thereof, is an ele-
ment of antibiotic resistance which must be given careful 
thought. The discrepancy in the availability of antibiot-
ics in developed and developing countries suggests a 
need for change in attitudes and policies. The costs of 
not addressing the rise in antimicrobial resistance could 
lead to an annual reduction in gross domestic product 
by 3–8% by the year 2050 with low- and middle-income 
countries being hit the hardest [51]. In many developing 
countries, particularly in rural areas, patients sometimes 
have no access to medical personnel, let alone antibiot-
ics. Meanwhile in larger towns and cities of these same 
countries, antibiotics are sold over the counter to those 
who can afford them even without a prescription from a 
healthcare professional [1]. In developed countries, there 
ends up being a surplus of available antibiotics, espe-
cially when administered unjustifiably [52]. In Germany, 
the total antibiotic consumption in human medicine 
is around 800 tons, of which 600 tons are used in out-
patient care, more than half of which are prescribed by 
GPs [50]. Though Germany is one those countries with a 
lower level of antibiotic consumption, the proportion of 
reserve antibiotics used is still high [50]. There is a need 
to balance access to essential medications, particularly in 
low- and middle-income countries where the burden of 
infectious diseases still outweighs the burden of resistant 
infections [53]. While we go about saving the antibiotics 
that we still have through good stewardship practices, 
many ethical questions must be asked, when looking at 
this problem from the perspective of a patient who has 
no hope of recovery from treatable infections, with no 
access to good healthcare and antibiotics. Besides this, 
we face the problem of a lack of availability of new anti-
biotics for several reasons, which cannot be dealt with in 
detail within the scope of this review. This aspect there-
fore needs to be tackled at the policy level especially 
when implementing regulations regarding the availabil-
ity, use and sale of antibiotics. Rochford et al. have rightly 
proposed an international agreement to ensure that anti-
biotics are available for future generations [51].
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Alternatives
Because antibiotic resistance is a problem that will not 
go away, it is important to have other alternatives. With 
this in mind it is essential, that the alternatives we look 
for are not necessarily substances that might replace the 
function of antibiotics per se, that is fight off infection, 
but methods and technologies that can support medicine 
in strengthening the immune system, besides preventing 
and treating infections.
Bacteriophages were used in 1917 by their discoverer 
Felix d’Herelle to successfully treat bacterial infections 
[54]. Due to the success with antibiotics later discov-
ered, bacteriophages were set aside, but very recently 
researchers and doctors at the University of California 
San Diego School of Medicine used novel phage therapy 
to treat a patient near death, suffering from an infection 
with a multidrug-resistant strain of Acinetobacter bau-
mannii, thus saving his life [55]. CRISPR technology is 
also being reviewed as an option to treat resistant infec-
tions [56, 57]. In 2016, Zipperer et  al. discovered that a 
human commensal Staphylococcus lugdunensis produces 
lugdunin, a novel antibiotic, which shows bactericidal 
activity against many major harmful bacteria, includ-
ing Methicillin-resistant Staphylococcus aureus (MRSA) 
and Vancomycin-resistant Enterococcus isolates, both of 
which are one of the major causes for concern for anti-
biotic resistance [58]. In 2018, Geldart et al. engineered 
the E. coli Nissle 1917 strain to produce and secrete anti-
microbial peptides to specifically target and kill Ente-
rococcus, with first results in a Vancomycin resistant 
Enterococcus (VRE) colonization mouse model appear-
ing very promising [59].
We would like to focus on the human microbiome as a 
promising alternative with its immense scope and poten-
tial, as well as the fact that new research provides increas-
ing evidence for links between the gut microbiome and 
health [60, 61]. The gut microbiota is known to play a role 
in anxiety, mood, cognition and pain which is exerted 
via the gut-brain axis and probiotics are frequently being 
used to treat a range of conditions including constipa-
tion, allergic reactions and infections [62]. In addition, 
the microbiome has already made headlines with a severe 
case of antibiotic resistance. A few years ago in a clinical 
trial, a faecal microbiota transplant (“Stool Transplant”) 
using purified intestinal bacterial cultures was success-
fully carried out in a patient suffering from a Clostridium 
difficile infection that had repeatedly failed standard anti-
biotics [63]. This is therefore a very promising method, 
given that in some cases it may be a last resort treatment 
option.
All of these promising technologies may not always 
be an easy solution, let alone feasible, especially in areas 
where access to basic healthcare and medicines is still a 
huge problem; however, these alternatives might soon 
be the only way forward. It may be a while before these 
methods become the new standard treatment, though 
from a global public health perspective, we need to take 
all these aspects into consideration when planning for a 
healthy future for every individual. Finally, if we do not 
find ways to tackle antibiotic resistance, we could find 
ourselves being afraid of a simple twig which could turn 
out to be a potentially deadly weapon.
Authors’ contributions
E‑MA drafted and wrote the manuscript. LHW and AL‑B were involved in 
revising the manuscript critically for important intellectual content. All authors 
read and approved the final manuscript.
Author details
1 Centre for Infection Medicine, Institute of Microbiology and Epizootics, 
Freie University Berlin, Robert‑von‑Ostertag Str. 7‑13, 14163 Berlin, Germany. 
2 Robert‑Koch‑Institute, Nordufer 20, 13353 Berlin, Germany. 3 Lindgrün 
GmbH, Cuxhavener Str. 12, 10557 Berlin, Germany. 4 Department of Biologi‑
cal Safety, German Federal Institute for Risk Assessment, Max‑Dohrn‑Str. 8‑10, 








This work is presented on behalf of the RAI Study group (Muna Abu Sin, Esther‑
Maria Antão, Michael Behnke, Evgeniya Boklage, Tim Eckmanns, Christina For‑
stner, Petra Gastmeier, Jochen Gensichen, Alexander Gropmann, Stefan Hagel, 
Regina Hanke, Wolfgang Hanke, Anja Klingeberg, Lukas Klimmek, Ulrich Kraft, 
Markus Lehmkuhl, Norman Ludwig, Antina Lübke‑Becker, Oliwia Makarewicz, 
Anne Moeser, Inga Petruschke, Mathias W. Pletz, Florian Salm, Katja Schmücker, 
Sandra Schneider, Christin Schröder, Frank Schwab, Joachim Trebbe, Szilvia 
Vincze, Horst Christian Vollmar, Jan Walter, Sebastian Weis, Wibke Wetzker, 
Lothar H. Wieler).
Ethics approval and consent to participate
Not applicable.
Funding
This work was supported by the German Federal Ministry of Education and 
Research (BMBF) within the consortium InfectControl 2020 (Project RAI, Grant 
ID 03ZZ0804B).
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in pub‑
lished maps and institutional affiliations.
Received: 6 September 2018   Accepted: 18 December 2018
References
 1. Morgan DJ, Okeke IN, Laxminarayan R, Perencevich EN, Weisenberg S. 
Non‑prescription antimicrobial use worldwide: a systematic review. 
Lancet Infect Dis. 2011;11(9):692–701.
 2. European Centre of Disease Control (ECDC). Last‑line antibiotics are 
failing: options to address this urgent threat to patients and healthcare 
systems. Stockholm: European Centre of Disease Control; 2016.
Page 8 of 9Antão et al. Gut Pathog           (2018) 10:52 
 3. WHO. Antimicrobial resistance fact sheet. Geneva: World Health 
Organization; 2017.
 4. Gastmeier P, Geffers C, Herrmann M, Lemmen S, Salzberger B, Seifert 
H, et al. Nosocomial infections and infections with multidrug‑resistant 
pathogens—frequency and mortality. Dtsch Med Wochenschr. 
2016;141(6):421–6.
 5. Maechler F, Geffers C, Schwab F, Pena Diaz LA, Behnke M, Gastmeier P. 
Development of antimicrobial resistance in Germany: what is the cur‑
rent situation? Med Klin Intensivmed Notfmed. 2017;112(3):186–91.
 6. Koppe U, von Laer A, Kroll LE, Noll I, Feig M, Schneider M, et al. Carbap‑
enem non‑susceptibility of Klebsiella pneumoniae isolates in hospitals 
from 2011 to 2016, data from the German Antimicrobial Resistance 
Surveillance (ARS). Antimicrob Resist Infect Control. 2018;7:71.
 7. Saunders LZ. Virchow’s contributions to veterinary medicine: cel‑
ebrated then, forgotten now. Vet Pathol. 2000;37(3):199–207.
 8. von Ostertag R. Handbook of meat inspection. New York: W.R. Jenkins; 
1904.
 9. Cardiff RD, Ward JM, Barthold SW. ‘One medicine—one pathol‑
ogy’: are veterinary and human pathology prepared? Lab Invest. 
2008;88(1):18–26.
 10. Cantas L, Suer K. Review: the important bacterial zoonoses in “one 
health” concept. Front Public Health. 2014;2:144.
 11. Vincze S, Schneider S, Lübke‑Becker A. One‑Health‑Konzept—Zusam‑
menhänge verstehen. Berlin: RAI “Rationaler Antibiotikaeinsatz durch 
Information und Kommunikation”; 2016.
 12. Ewers C, Bethe A, Semmler T, Guenther S, Wieler LH. Extended‑
spectrum beta‑lactamase‑producing and AmpC‑producing Escheri-
chia coli from livestock and companion animals, and their putative 
impact on public health: a global perspective. Clin Microbiol Infect. 
2012;18(7):646–55.
 13. Ewers C, Bethe A, Stamm I, Grobbel M, Kopp PA, Guerra B, et al. CTX‑M‑
15‑D‑ST648 Escherichia coli from companion animals and horses: another 
pandemic clone combining multiresistance and extraintestinal virulence? 
J Antimicrob Chemother. 2014;69(5):1224–30.
 14. Schaufler K, Bethe A, Lubke‑Becker A, Ewers C, Kohn B, Wieler LH, et al. 
Putative connection between zoonotic multiresistant extended‑spec‑
trum beta‑lactamase (ESBL)‑producing Escherichia coli in dog feces from 
a veterinary campus and clinical isolates from dogs. Infect Ecol Epidemiol. 
2015;5:25334.
 15. Schaufler K, Semmler T, Wieler LH, Wohrmann M, Baddam R, Ahmed N, 
et al. Clonal spread and interspecies transmission of clinically relevant 
ESBL‑producing Escherichia coli of ST410–another successful pandemic 
clone? FEMS Microbiol Ecol. 2016;92:1.
 16. McNally A, Oren Y, Kelly D, Pascoe B, Dunn S, Sreecharan T, et al. Com‑
bined analysis of variation in core, accessory and regulatory genome 
regions provides a super‑resolution view into the evolution of bacterial 
populations. PLoS Genet. 2016;12(9):e1006280.
 17. Guenther S, Semmler T, Stubbe A, Stubbe M, Wieler LH, Schaufler K. 
Chromosomally encoded ESBL genes in Escherichia coli of ST38 from 
Mongolian wild birds. J Antimicrob Chemother. 2017;72:1310–3.
 18. Ahasan MS, Picard J, Elliott L, Kinobe R, Owens L, Ariel E. Evidence of 
antibiotic resistance in Enterobacteriales isolated from green sea turtles, 
Chelonia mydas on the Great Barrier Reef. Mar Pollut Bull. 2017;120:18–27.
 19. Lubbert C, Straube L, Stein C, Makarewicz O, Schubert S, Mossner J, et al. 
Colonization with extended‑spectrum beta‑lactamase‑producing and 
carbapenemase‑producing Enterobacteriaceae in international travelers 
returning to Germany. Int J Med Microbiol. 2015;305(1):148–56.
 20. Barreto Miranda I, Ignatius R, Pfuller R, Friedrich‑Janicke B, Steiner F, 
Paland M, et al. High carriage rate of ESBL‑producing Enterobacteriaceae 
at presentation and follow‑up among travellers with gastrointestinal 
complaints returning from India and Southeast Asia. J Travel Med. 
2016;23(2):024.
 21. Bengtsson‑Palme J, Angelin M, Huss M, Kjellqvist S, Kristiansson E, 
Palmgren H, et al. The human gut microbiome as a transporter of 
antibiotic resistance genes between continents. Antimicrob Agents 
Chemother. 2015;59(10):6551–60.
 22. Cuny C, Wieler LH, Witte W. Livestock‑associated MRSA: the impact on 
humans. Antibiotics (Basel). 2015;4(4):521–43.
 23. Walther B, Tedin K, Lubke‑Becker A. Multidrug‑resistant opportunistic 
pathogens challenging veterinary infection control. Vet Microbiol. 
2017;200:71–8.
 24. Walther B, Hermes J, Cuny C, Wieler LH, Vincze S, Abou Elnaga Y, et al. 
Sharing more than friendship–nasal colonization with coagulase‑positive 
staphylococci (CPS) and co‑habitation aspects of dogs and their owners. 
PLoS ONE. 2012;7(4):e35197.
 25. Walther B, Wieler LH, Vincze S, Antao EM, Brandenburg A, Stamm 
I, et al. MRSA variant in companion animals. Emerg Infect Dis. 
2012;18(12):2017–20.
 26. Vincze S, Stamm I, Monecke S, Kopp PA, Semmler T, Wieler LH, et al. 
Molecular analysis of human and canine Staphylococcus aureus strains 
reveals distinct extended‑host‑spectrum genotypes independent of their 
methicillin resistance. Appl Environ Microbiol. 2013;79(2):655–62.
 27. Vincze S, Stamm I, Kopp PA, Hermes J, Adlhoch C, Semmler T, et al. Alarm‑
ing proportions of methicillin‑resistant Staphylococcus aureus (MRSA) in 
wound samples from companion animals, Germany 2010–2012. PLoS 
ONE. 2014;9(1):e85656.
 28. Paterson GK, Harrison EM, Murray GG, Welch JJ, Warland JH, Holden MT, 
et al. Capturing the cloud of diversity reveals complexity and hetero‑
geneity of MRSA carriage, infection and transmission. Nat Commun. 
2015;6:6560.
 29. Hussain A, Shaik S, Ranjan A, Nandanwar N, Tiwari SK, Majid M, et al. Risk 
of transmission of antimicrobial resistant Escherichia coli from commercial 
broiler and free‑range retail chicken in India. Front Microbiol. 2017;8:2120.
 30. D’Costa VM, King CE, Kalan L, Morar M, Sung WW, Schwarz C, et al. Antibi‑
otic resistance is ancient. Nature. 2011;477(7365):457–61.
 31. D’Costa VM, McGrann KM, Hughes DW, Wright GD. Sampling the antibi‑
otic resistome. Science. 2006;311(5759):374–7.
 32. Schneider S, Salm F, Vincze S, Moeser A, Petruschke I, Schmucker K, et al. 
Perceptions and attitudes regarding antibiotic resistance in Germany: a 
cross‑sectoral survey amongst physicians, veterinarians, farmers and the 
general public. J Antimicrob Chemother. 2018;73:1984–8.
 33. Vincze S, Antão E, Lübke‑Becker A. Selektion und Resistenzmechanis‑
men—Entstehung und Ausbreitung resistenter Bakterien. Berlin: RAI 
“Rationaler Antibiotikaeinsatz durch Information und Kommunikation”; 
2017.
 34. Malhotra‑Kumar S, Xavier BB, Das AJ, Lammens C, Butaye P, Goossens 
H. Colistin resistance gene mcr‑1 harboured on a multidrug resistant 
plasmid. Lancet Infect Dis. 2016;16(3):283–4.
 35. Dyar OJ, Huttner B, Schouten J, Pulcini C, Esgap. What is antimicrobial 
stewardship? Clin Microbiol Infect. 2017;23(11):793–8.
 36. Pulcini C. Antibiotic stewardship: a European perspective. FEMS Microbiol 
Lett. 2017;364:23.
 37. Pulcini C, Mainardi JL. Antimicrobial stewardship: an international emer‑
gency. Clin Microbiol Infect. 2014;20(10):947–8.
 38. Vincze S, Lübke‑Becker A. Antibiotika: Gut zu wissen—grundlagen der 
pharmakologie. Berlin: RAI “Rationaler Antibiotikaeinsatz durch Informa‑
tion und Kommunikation”; 2016.
 39. Ocampo PS, Lazar V, Papp B, Arnoldini M, AbelzurWiesch P, Busa‑Fekete R, 
et al. Antagonism between bacteriostatic and bactericidal antibiotics is 
prevalent. Antimicrob Agents Chemother. 2014;58(8):4573–82.
 40. Bollenbach T. Antimicrobial interactions: mechanisms and implica‑
tions for drug discovery and resistance evolution. Curr Opin Microbiol. 
2015;27:1–9.
 41. WHO. WHO updates Essential Medicines List with new advice on use 
of antibiotics, and adds medicines for hepatitis C, HIV, tuberculosis, and 
cancer [press release]. Geneva: World Health Organization; 2017.
 42. Salm F, Ernsting C, Kuhlmey A, Kanzler M, Gastmeier P, Gellert P. Anti‑
biotic use, knowledge and health literacy among the general popula‑
tion in Berlin, Germany and its surrounding rural areas. PLoS ONE. 
2018;13(2):e0193336.
 43. Alberta Health Services and the British Columbia Centre for Disease 
Control. Do bugs need drugs: a community program for wise use of anti‑
biotics. Alberta: Alberta Health Services and the British Columbia Centre 
for Disease Control; 2015.
 44. Public Health England. Antibiotic awareness: quizzes and crosswords. 
London: Public Health England; 2014.
 45. Ministry of Health and Animal Welfare, Government of India. National 
Action Plan on Antimicrobial Resistance (NAP‑AMR) 2017–2021. Chennai: 
Ministry of Health and Animal Welfare, Government of India; 2017.
 46. WHO. World antibiotic awareness week. Geneva: WHO; 2017.
 47. Birgand G, Castro‑Sanchez E, Hansen S, Gastmeier P, Lucet JC, Ferlie 
E, et al. Comparison of governance approaches for the control of 
Page 9 of 9Antão et al. Gut Pathog           (2018) 10:52 
•
 
fast, convenient online submission
 •
  
thorough peer review by experienced researchers in your field
• 
 
rapid publication on acceptance
• 
 
support for research data, including large and complex data types
•
  
gold Open Access which fosters wider collaboration and increased citations 
 
maximum visibility for your research: over 100M website views per year •
  At BMC, research is always in progress.
Learn more biomedcentral.com/submissions
Ready to submit your research ?  Choose BMC and benefit from: 
antimicrobial resistance: analysis of three European countries. Antimicrob 
Resist Infect Control. 2018;7:28.
 48. DART 2020. Antibiotika‑Resistenzen bekämpfen zum Wohl von Mensch 
und Tier. Berlin: Bundesministerium für Gesundheit (BMG), Bundesminis‑
terium für Ernährung und Landwirtschaft (BMEL), Bundesministerium für 
Bildung und Forschung (BMBF); 2015.
 49. Neue Antiinfektionsstrategien: Wissenschaft, Gesellschaft, Wirtschaft. 
Jena: Fördermaßnahme “Zwanzig20—Partnerschaft für Innovation” des 
Bundesministeriums für Bildung und Forschung (BMBF); 2014.
 50. Salm F, Schneider S, Schmucker K, Petruschke I, Kramer TS, Hanke R, 
et al. Antibiotic prescribing behavior among general practitioners—a 
questionnaire‑based study in Germany. BMC Infect Dis. 2018;18(1):208.
 51. Rochford C, Sridhar D, Woods N, Saleh Z, Hartenstein L, Ahlawat H, 
Whiting E, Dybul M, Cars O, Goosby E, Cassels A. Global governance of 
antimicrobial resistance. Lancet. 2018;391(10134):1976–8.
 52. Antao EM, Wagner‑Ahlfs C. Antibiotic resistance: a challenge for society. 
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 
2018;61(5):499–506.
 53. Klein EY, Van Boeckel TP, Martinez EM, Pant S, Gandra S, Levin SA, et al. 
Global increase and geographic convergence in antibiotic consumption 
between 2000 and 2015. Proc Natl Acad Sci USA. 2018;115:E3463.
 54. Golkar Z, Bagasra O, Pace DG. Bacteriophage therapy: a potential solution 
for the antibiotic resistance crisis. J Infect Dev Ctries. 2014;8(2):129–36.
 55. UC SanDiego Health. Novel phage therapy saves patient with multidrug‑
resistant bacterial infection [press release]. SanDiego: UC SanDiego 
Health; 2017.
 56. Mullin E. Edible CRISPR could replace antibiotics. MIT Technol Rev. 2017. 
https ://www.techn ology revie w.com/s/60412 6/edibl e‑crisp r‑could ‑repla 
ce‑antib iotic s/.
 57. Bikard D, Euler CW, Jiang W, Nussenzweig PM, Goldberg GW, Duportet 
X, et al. Exploiting CRISPR‑–Cas nucleases to produce sequence‑specific 
antimicrobials. Nat Biotechnol. 2014;32(11):1146–50.
 58. Zipperer A, Konnerth MC, Laux C, Berscheid A, Janek D, Weidenmaier C, 
et al. Human commensals producing a novel antibiotic impair pathogen 
colonization. Nature. 2016;535(7613):511–6.
 59. Geldart KG, Kommineni S, Forbes M, Hayward M, Dunny GM, Salzman 
NH, et al. Engineered E. coli Nissle 1917 for the reduction of vancomy‑
cin‑resistant Enterococcus in the intestinal tract. Bioeng Transl Med. 
2018;3(3):197–208.
 60. Thaiss CA, Levy M, Grosheva I, Zheng D, Soffer E, Blacher E, et al. Hypergly‑
cemia drives intestinal barrier dysfunction and risk for enteric infection. 
Science. 2018;359(6382):1376–83.
 61. Chassaing B. The intestinal microbiota helps shapping the adaptive 
immune response against viruses. Med Sci (Paris). 2015;31(4):355–7.
 62. Mohajeri MH, Brummer RJM, Rastall RA, Weersma RK, Harmsen HJM, Faas 
M, et al. The role of the microbiome for human health: from basic science 
to clinical applications. Eur J Nutr. 2018;5:1–4.
 63. Petrof EO, Gloor GB, Vanner SJ, Weese SJ, Carter D, Daigneault MC, et al. 
Stool substitute transplant therapy for the eradication of Clostridium dif-
ficile infection: ‘RePOOPulating’ the gut. Microbiome. 2013;1(1):3.
